TY - JOUR
T1 - Rapid, accurate publication and dissemination of clinical trial results
T2 - benefits and challenges
AU - Zannad, Faiez
AU - Crea, Filippo
AU - Keaney, John
AU - Spencer, Stuart
AU - Hill, Joseph A.
AU - Pfeffer, Marc A.
AU - Pocock, Stuart
AU - Raderschadt, Emma
AU - Ross, Joseph S.
AU - Sacks, Chana A.
AU - Van Spall, Harriette G.C.
AU - Winslow, Ron
AU - Jessup, Mariell
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2023/10/21
Y1 - 2023/10/21
N2 - Large-scale clinical trials are essential in cardiology and require rapid, accurate publication, and dissemination. Whereas conference presentations, press releases, and social media disseminate information quickly and often receive considerable coverage by mainstream and healthcare media, they lack detail, may emphasize selected data, and can be open to misinterpretation. Preprint servers speed access to research manuscripts while awaiting acceptance for publication by a journal, but these articles are not formally peer-reviewed and sometimes overstate the findings. Publication of trial results in a major journal is very demanding but the use of existing checklists can help accelerate the process. In case of rejection, procedures such as easing formatting requirements and possibly carrying over peer-review to other journals could speed resubmission. Secondary publications can help maximize benefits from clinical trials; publications of secondary endpoints and subgroup analyses further define treatment effects and the patient populations most likely to benefit. These rely on data access, and although data sharing is becoming more common, many challenges remain. Beyond publication in medical journals, there is a need for wider knowledge dissemination to maximize impact on clinical practice. This might be facilitated through plain language summary publications. Social media, websites, mainstream news outlets, and other publications, although not peer-reviewed, are important sources of medical information for both the public and for clinicians. This underscores the importance of ensuring that the information is understandable, accessible, balanced, and trustworthy. This report is based on discussions held on December 2021, at the 18th Global Cardiovascular Clinical Trialists meeting, involving a panel of editors of some of the top medical journals, as well as members of the lay press, industry, and clinical trialists.
AB - Large-scale clinical trials are essential in cardiology and require rapid, accurate publication, and dissemination. Whereas conference presentations, press releases, and social media disseminate information quickly and often receive considerable coverage by mainstream and healthcare media, they lack detail, may emphasize selected data, and can be open to misinterpretation. Preprint servers speed access to research manuscripts while awaiting acceptance for publication by a journal, but these articles are not formally peer-reviewed and sometimes overstate the findings. Publication of trial results in a major journal is very demanding but the use of existing checklists can help accelerate the process. In case of rejection, procedures such as easing formatting requirements and possibly carrying over peer-review to other journals could speed resubmission. Secondary publications can help maximize benefits from clinical trials; publications of secondary endpoints and subgroup analyses further define treatment effects and the patient populations most likely to benefit. These rely on data access, and although data sharing is becoming more common, many challenges remain. Beyond publication in medical journals, there is a need for wider knowledge dissemination to maximize impact on clinical practice. This might be facilitated through plain language summary publications. Social media, websites, mainstream news outlets, and other publications, although not peer-reviewed, are important sources of medical information for both the public and for clinicians. This underscores the importance of ensuring that the information is understandable, accessible, balanced, and trustworthy. This report is based on discussions held on December 2021, at the 18th Global Cardiovascular Clinical Trialists meeting, involving a panel of editors of some of the top medical journals, as well as members of the lay press, industry, and clinical trialists.
KW - Data sharing
KW - Plain-language summary
KW - Preprint services
KW - Press releases
KW - Secondary analyses
UR - http://www.scopus.com/inward/record.url?scp=85176344306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176344306&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehad279
DO - 10.1093/eurheartj/ehad279
M3 - Review article
C2 - 37165687
AN - SCOPUS:85176344306
SN - 0195-668X
VL - 44
SP - 4220
EP - 4229
JO - European heart journal
JF - European heart journal
IS - 40
ER -